GoodRx Holdings, Inc. (NASDAQ:GDRX) Given Consensus Rating of “Hold” by Brokerages

GoodRx Holdings, Inc. (NASDAQ:GDRX) has received an average rating of “Hold” from the fourteen analysts that are presently covering the firm, MarketBeat reports. Three analysts have rated the stock with a sell rating, six have given a hold rating and five have given a buy rating to the company. The average 12-month price target among brokerages that have issued ratings on the stock in the last year is $4.7292.

A number of equities analysts have recently issued reports on the company. Barclays initiated coverage on GoodRx in a report on Monday, December 8th. They issued an “underweight” rating and a $3.00 target price for the company. Jefferies Financial Group cut GoodRx to a “hold” rating in a research report on Thursday. Mizuho dropped their price objective on GoodRx from $5.00 to $4.00 and set a “neutral” rating for the company in a research note on Thursday, November 6th. Citigroup reduced their target price on shares of GoodRx from $5.00 to $4.50 and set a “buy” rating on the stock in a research note on Friday, January 9th. Finally, Wall Street Zen cut shares of GoodRx from a “buy” rating to a “hold” rating in a research report on Sunday.

Institutional Inflows and Outflows

A number of institutional investors have recently modified their holdings of the company. Quarry LP bought a new stake in GoodRx during the 3rd quarter worth approximately $33,000. Boothbay Fund Management LLC bought a new position in GoodRx in the 3rd quarter valued at $43,000. Shay Capital LLC acquired a new position in GoodRx in the third quarter worth $47,000. Cetera Investment Advisers acquired a new position in GoodRx in the second quarter worth $50,000. Finally, Walled Lake Planning & Wealth Management LLC bought a new stake in shares of GoodRx during the second quarter worth $55,000. Institutional investors own 63.77% of the company’s stock.

GoodRx Price Performance

Shares of GoodRx stock opened at $2.56 on Monday. The firm has a market cap of $868.94 million, a P/E ratio of 28.44, a price-to-earnings-growth ratio of 0.97 and a beta of 1.45. The firm’s 50-day simple moving average is $2.75 and its 200-day simple moving average is $3.65. GoodRx has a twelve month low of $2.47 and a twelve month high of $5.81. The company has a debt-to-equity ratio of 0.81, a quick ratio of 3.11 and a current ratio of 3.11.

GoodRx (NASDAQ:GDRX) last posted its quarterly earnings results on Tuesday, November 4th. The company reported $0.08 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.09 by ($0.01). The business had revenue of $196.03 million during the quarter, compared to analyst estimates of $195.17 million. GoodRx had a return on equity of 9.73% and a net margin of 3.97%.The business’s revenue for the quarter was up .4% on a year-over-year basis. During the same period last year, the company earned $0.08 EPS. As a group, research analysts expect that GoodRx will post 0.13 EPS for the current fiscal year.

GoodRx Company Profile

GoodRx Holdings, Inc (NASDAQ: GDRX) operates a digital healthcare platform designed to help consumers compare prescription drug prices at retail pharmacies across the United States. Through its website and mobile applications, GoodRx aggregates pricing and discount information from a wide network of pharmacies, enabling users to access coupons and savings programs on both generic and brand-name medications. The platform also features price transparency tools that inform patients about cost variations and available discounts to alleviate the financial burden of prescription medications.

In addition to its core drug pricing service, GoodRx offers telehealth services under the GoodRx Care brand, providing virtual consultations for a range of non-emergency conditions and prescription needs.